BR112013010340A2 - concentrado de solução, e, método de estabilização do ingrediente farmacêutico atiuvo em uma solução concentrada para administração oral - Google Patents

concentrado de solução, e, método de estabilização do ingrediente farmacêutico atiuvo em uma solução concentrada para administração oral

Info

Publication number
BR112013010340A2
BR112013010340A2 BR112013010340A BR112013010340A BR112013010340A2 BR 112013010340 A2 BR112013010340 A2 BR 112013010340A2 BR 112013010340 A BR112013010340 A BR 112013010340A BR 112013010340 A BR112013010340 A BR 112013010340A BR 112013010340 A2 BR112013010340 A2 BR 112013010340A2
Authority
BR
Brazil
Prior art keywords
solution
stabilizing
oral administration
active pharmaceutical
pharmaceutical ingredient
Prior art date
Application number
BR112013010340A
Other languages
English (en)
Inventor
Anna W Tai
Dennis Nelson
Joseph P Reo
Kevin C Fowler
Michael P Tune
Mohamed A Kabir
Nanhye Kim
Original Assignee
Msd Consumer Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Consumer Care Inc filed Critical Msd Consumer Care Inc
Publication of BR112013010340A2 publication Critical patent/BR112013010340A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

concentrado de solução, e, método de estabilização do ingrediente farmacêutico atiuvo em uma solução concentrada para administração oral. uma solução de poli(etileno glicol) concentrada tendo boa estabilidade para armazenagem estendida é fornecida para o uso como laxante. a solução concentrada compreende água, benzoato de sódio, poli(etileno glicol) e ácido o bastante para a produção de uma solução tendo um ph a 25°c na faixa de 3,0 a 5,0. esta é preparada e acondicionada para minimizar o acúmulo de produtos de degradação.
BR112013010340A 2010-10-29 2011-10-24 concentrado de solução, e, método de estabilização do ingrediente farmacêutico atiuvo em uma solução concentrada para administração oral BR112013010340A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40796910P 2010-10-29 2010-10-29
PCT/US2011/057494 WO2012058157A1 (en) 2010-10-29 2011-10-24 Therapeutic solution concentrate

Publications (1)

Publication Number Publication Date
BR112013010340A2 true BR112013010340A2 (pt) 2016-08-02

Family

ID=45994344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010340A BR112013010340A2 (pt) 2010-10-29 2011-10-24 concentrado de solução, e, método de estabilização do ingrediente farmacêutico atiuvo em uma solução concentrada para administração oral

Country Status (8)

Country Link
US (2) US20120220654A1 (pt)
EP (1) EP2632578A4 (pt)
AU (1) AU2011320635B2 (pt)
BR (1) BR112013010340A2 (pt)
CA (1) CA2817068C (pt)
MX (1) MX360848B (pt)
RU (1) RU2576026C2 (pt)
WO (1) WO2012058157A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937130A (en) * 1989-01-18 1990-06-26 General Electric Company Polycarbonate container having internal layers of amorphous polyamide
MX9303141A (es) * 1992-05-28 1994-04-29 Polar Materials Inc Metodos y aparatos para depositar recubrimientos de barrera.
WO1998012127A1 (en) * 1996-09-23 1998-03-26 Amoco Corporation Zero oxygen permeation plastic bottle for beer and other applications
RU2005134364A (ru) * 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
GB0403702D0 (en) * 2004-02-19 2004-03-24 Boots Co Plc Skincare compositions
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
DE10358213A1 (de) * 2003-12-12 2005-07-28 Clariant Gmbh Polyethylenglykol und dessen Herstellung
CA2607250C (en) * 2005-05-06 2012-11-06 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
US7423888B2 (en) * 2005-06-08 2008-09-09 Tamura Corporation Voltage conversion circuit and switching power supply device
WO2007005955A2 (en) * 2005-06-30 2007-01-11 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
CA2817068A1 (en) 2012-05-03
EP2632578A4 (en) 2014-12-03
MX360848B (es) 2018-11-20
WO2012058157A1 (en) 2012-05-03
US20140080918A1 (en) 2014-03-20
CA2817068C (en) 2020-04-21
RU2576026C2 (ru) 2016-02-27
EP2632578A1 (en) 2013-09-04
MX2013004736A (es) 2013-06-05
AU2011320635B2 (en) 2016-02-04
RU2013124831A (ru) 2014-12-10
AU2011320635A1 (en) 2013-05-02
US20120220654A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
BR112015011179A8 (pt) composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
BR112014032809A8 (pt) urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas
NI201200152A (es) Formulaciones de insulina de acción prolongada.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
ECSP13013010A (es) Preparación de gadobutrol de alta pureza
BR112012018695A2 (pt) compostos pirazol como antagonistas crth2
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
NI201100218A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CR11825A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
AR077347A1 (es) Mejoramientos en composiciones farmaceuticas y relacionados con ellas
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
MX2012010935A (es) Formulacion acuosa estable mejorada de (e)-4-carboxiestiril-4-clor obencil sulfona.
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112013010340A2 (pt) concentrado de solução, e, método de estabilização do ingrediente farmacêutico atiuvo em uma solução concentrada para administração oral

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: MSD CONSUMER CARE, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BAYER CONSUMER CARE HOLDINGS LLC (US)

B25A Requested transfer of rights approved

Owner name: BAYER CONSUMER CARE AG (CH)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]